The company notes that this uplift may not continue in full into the next financial year due to the uncertain and changeable outlook for COVID-19 vaccination and swabbing activity”.
Printable View
The company notes that this uplift may not continue in full into the next financial year due to the uncertain and changeable outlook for COVID-19 vaccination and swabbing activity”.
Probably sold a bit of panadol and a few more masks yesterday.......:sleep:
Who needs Competition when the Competition are as good as this :
https://www.stuff.co.nz/business/127...-customer-4000
Chemist Warehouse overcharges customer $4000
;)
GXH share did very well compared to broader market - in fact share price didn't fall at all. They must be doing really well thanks to omicron outbreak - swabbing, RAT tests, vaccinations, local doctor clinics etc
Buyer/seller depth has also increased significantly. Cheapest healthcare stock:t_up:
Discl - added a few more yesterday
Trading update March 2022 - NZX, New Zealand’s Exchange
Green Cross Health (NZX:GXH) continues to experience higher than anticipated revenue and profitability relative to the prior period. For the 11 months to 28 February 2022, the company has experienced an increase in revenue of approximately 16%.
Group CEO Rachael Newfield said “COVID-19 related activity across the company’s three divisions of Medical, Pharmacy and Community Health as well as the impact of recent acquisitions in the Medical division, continue to be the key contributors to the elevated performance levels. The company notes that this level of performance is not expected to continue into the next financial year.”
Net Profit After Tax Attributable to Shareholders for the 12 months to 31 March 2022 is projected to exceed the prior period result by $9.0m - $10.5m1 (25 January 2022 guidance $4.5m – $6.5m increase on prior period).
Green Cross Health is scheduled to release its audited full year result for the year to 31 March 2022 on 27 May 2022.
1 $10.5m - $12.0m excluding extraordinary amounts.
ENDS
Excellent update - as expected due to surging omicron
A tight share register - this is what happens with buying interest & limited shares coming on the market IMO
Forget whether growth priced in or not in this case :)
Tightly held share registry/low liquidity etc shouldn't concern a retail investor - such issues are a problem for mutual funds/institutions. That's why funds don't own much of GXH. Briscoes and STU are also similar. I like companies with low institutional ownership:)